Abstract

Pharmacy directors say that recent proposals for changes to the 340B Drug Pricing Program are shortsighted and will lead to adverse outcomes for patients. “This would be a major setback,” said Bob Ripley, vice president and chief pharmacy officer tor Trinity Health in Livonia, Michigan. Ripley

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call